Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 May;34(5):1232–1234. doi: 10.1128/jcm.34.5.1232-1234.1996

Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University.

A Vasquez 1, Y Valdez 1, R H Gilman 1, J J McDonald 1, T U Westblom 1, D Berg 1, H Mayta 1, V Gutierrez 1
PMCID: PMC228988  PMID: 8727909

Abstract

Resistance of Helicobacter pylori to metronidazole often causes failure of commonly used combination drug treatment regimens. We determined the MICs of metronidazole and clarithromycin against 18 H. pylori strains from Peru using tetrazolium egg yolk (TEY) agar. The MIC results obtained by agar dilution with petri dishes were compared with the results found through a miniwell format. The results of the two protocols for measuring drug susceptibility differed by no more than 1 dilution in all cases. On TEY agar, bright-red H. pylori colonies were easy to identify against a yellow background. Sixty-one percent (11 of 18) of the strains were resistant to metronidazole (MIC, > or = 4 micrograms/ml) and 50% (9 of 18) were resistant to clarithromycin (MIC, > or = 0.125 micrograms/ml), whereas none (0 of 5) of the strains tested were resistant to tetracycline (MIC, > or = 1 micrograms/ml). Thus, the prevalence of metronidazole and clarithromycin resistance in Peru is higher than that in developed regions of the world. The miniwell plate with TEY agar allows easy H. pylori colony identification, requires about one-third less of the costly medium necessary for petri dish assaying, conserves space, and yields MICs equivalent to those with agar dilution in petri dishes.

Full Text

The Full Text of this article is available as a PDF (347.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger S. A., Gorea A., Moskowitz M., Santo M., Gilat T. Effect of inoculum size on antimicrobial susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1993 Oct;12(10):782–783. doi: 10.1007/BF02098470. [DOI] [PubMed] [Google Scholar]
  2. DeCross A. J., Marshall B. J., McCallum R. W., Hoffman S. R., Barrett L. J., Guerrant R. L. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol. 1993 Aug;31(8):1971–1974. doi: 10.1128/jcm.31.8.1971-1974.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Leon-Barua R., Recavarren-Arce S., Gilman R. H., Berendson R. Can eradication of Helicobacter pylori prevent gastric cancer? Gastrointestinal Physiology Working Group of Cayetano Heredia. Drugs. 1993 Sep;46(3):341–346. doi: 10.2165/00003495-199346030-00001. [DOI] [PubMed] [Google Scholar]
  4. Malanoski G. J., Eliopoulos G. M., Ferraro M. J., Moellering R. C., Jr Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):131–133. doi: 10.1007/BF01967591. [DOI] [PubMed] [Google Scholar]
  5. Noach L. A., Langenberg W. L., Bertola M. A., Dankert J., Tytgat G. N. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis. 1994;26(3):321–327. doi: 10.3109/00365549409011802. [DOI] [PubMed] [Google Scholar]
  6. Nomura A., Stemmermann G. N., Chyou P. H., Kato I., Perez-Perez G. I., Blaser M. J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991 Oct 17;325(16):1132–1136. doi: 10.1056/NEJM199110173251604. [DOI] [PubMed] [Google Scholar]
  7. Parsonnet J., Friedman G. D., Vandersteen D. P., Chang Y., Vogelman J. H., Orentreich N., Sibley R. K. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct 17;325(16):1127–1131. doi: 10.1056/NEJM199110173251603. [DOI] [PubMed] [Google Scholar]
  8. Queiroz D. M., Mendes E. N., Rocha G. A. Indicator medium for isolation of Campylobacter pylori. J Clin Microbiol. 1987 Dec;25(12):2378–2379. doi: 10.1128/jcm.25.12.2378-2379.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Seppälä K., Färkkilä M., Nuutinen H., Hakala K., Vänänen H., Rautelin H., Kosunen T. U. Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients. Scand J Gastroenterol. 1992 Nov;27(11):973–976. doi: 10.3109/00365529209000173. [DOI] [PubMed] [Google Scholar]
  10. Tytgat G. N., Noach L. A., Rauws E. A. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am. 1993 Mar;22(1):127–139. [PubMed] [Google Scholar]
  11. Westblom T. U., Madan E., Midkiff B. R. Egg yolk emulsion agar, a new medium for the cultivation of Helicobacter pylori. J Clin Microbiol. 1991 Apr;29(4):819–821. doi: 10.1128/jcm.29.4.819-821.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. de Boer W., Driessen W., Jansz A., Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995 Apr 1;345(8953):817–820. doi: 10.1016/s0140-6736(95)92962-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES